Table 1.
Clinical features at baseline and during follow up
| Total | Incident | |
|---|---|---|
| N = 448 | N = 448 | |
| Baseline, number (%) | Follow up, number | |
| Vascular involvement | 430 (96.0) | 10 |
| Raynaud phenomenon | 424 (94.6) | 11 |
| Fingertip ulcer | 128 (28.6) | 19 |
| Loss of finger pad | 137 (30.6) | 20 |
| Telangiectasia | 153 (34.2) | 39 |
| Arthritis | 121 (27.0) | 66 |
| Muscle involvement | 44 (9.8) | 11 |
| Pulmonary interstitial disease (ILD)a | 358/447 (80.1) | 24 |
| Pulmonary arterial hypertension (PAH) | 67/359 (18.7) | 11 |
| Gastrointestinal involvement | 274 (61.2) | 38 |
| Esophagus | 243 (54.2) | 40 |
| Gastric | 115 (25.7) | 20 |
| Intestinal | 67 (15.0) | 13 |
| Cardiac involvement | 177/397 (44.6) | 97/411 |
| Arrhythmia | 16/396 (4.0) | 13/412 |
| LVEF < 50% | 1/396 (0.3) | 3/411 |
| Left ventricular diastolic dysfunction | 69/396 (17.4) | 70/411 |
| Pericardial effusion | 57/396 (14.4) | 53/411 |
| Valvular disease | 88/396 (22.2) | 70/412 |
| Renal crisis | 5 (1.1) | 0 |
| Skin Rodnan score | 6 (0, 43) | – |
LVEF left ventricular ejection fraction
aPulmonary interstitial disease: one patient diagnosed with silicosis at first visit was excluded